6 news items
EXCLUSIVE: Vivani Medical's Type 2 Diabetes Treatment NPM-119 Subdermal Implant's IND Gains FDA Clearance For Clinical Use (UPDATED)
VANI
13 Jun 24
its NanoPortal technology. These implants aim to improve medication adherence and outcomes in chronic diseases like type 2 diabetes and chronic
Vivani Medical Announces Publication of Positive Weight Loss Data Supporting Potential Veterinary Use of OKV-119 Miniature, Long-term GLP-1 Implant
VANI
28 May 24
" or the "Company"), a biopharmaceutical company developing miniaturized, long-term drug implants including its lead asset NPM-115 for chronic weight management
EXCLUSIVE: Vivani Medical Highlights Weight Loss Data For GLP-1 Implant Supporting Potential Veterinary Use
VANI
28 May 24
efforts to clinically evaluate our miniature, subdermal GLP-1 implants for the treatment of chronic weight management in obese or overweight human
Vivani Medical Provides Business Update and Reports First Quarter 2024 Financial Results
VANI
13 May 24
continues advancing the development of miniature, long-term GLP-1 implants for the treatment of chronic weight management in obese or overweight patients
Vivani Medical to Present at TIDES Conference 2024
VANI
9 May 24
) ("Vivani" or the "Company"), a biopharmaceutical company developing miniaturized, long-term drug implants including its lead asset NPM-115 for chronic
ntcuul1tkc417fp2ageg qoe61qtav6xql2jg4fk
VANI
26 Mar 24
shift prioritizes the development of GLP-1 implants for the treatment of obesity and chronic weight management
- Prev
- 1
- Next